News

September 19, 2017September 19, 2017

Janssen Submits Supplemental New Drug Application for Zytiga to Treat Metastatic Prostate Cancer

Janssen Biotech seeks U.S. approval to use a triple combination treatment with Zytiga (abiraterone acetate), prednisone and androgen deprivation therapy (ADT) for men with high-risk metastatic hormone naïve prostate cancer (HNPC) ... Read more

September 18, 2017

Xtandi Seen to Delay Metastasis in Castration-resistant Prostate Cancer, Trial Shows

News

Adding Xtandi (enzalutamide) to hormone therapy reduces the risk of cancer spreading in patients with non-metastatic castration-resistant prostate cancer (CRPC), new Phase 3 trial data shows. Additional results announced by ... Read more

September 15, 2017

Myriad Genetics Marking Prostate Cancer Awareness Month with Hereditary Testing Outreach

News

Myriad Genetics is marking Prostate Cancer Awareness Month by highlighting the importance of assessing the hereditary risk of the disease. The company is using its myRisk Hereditary Cancer test in its public outreach ... Read more

September 14, 2017

Favorable Interim Data Presented for Tyme’s SM-88 Phase 2 Trial for Prostate Cancer Patients

News

Tyme Technologies‘ SM-88 reduced the levels of circulating cancer cells — an indicator of metastatic disease — in all prostate cancer patients treated in an ongoing Phase 2 trial, ... Read more

September 13, 2017

Hormone Depletion Activates Tumor Survival Process in Prostate Cancer, Study Shows

News

Prostate cancer hormone depletion treatments might, in fact, be boosting cancer growth and making a tumor more aggressive, researchers at England’s University of Surrey found. Their study, which appeared in the ... Read more

September 12, 2017September 12, 2017

Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds

News

Two treatment approaches — Zytiga (abiraterone acetate) plus prednisolone (AAP) or Taxotere (docetaxel) — provided patients with high-risk prostate cancer similar benefits when added to standard hormone deprivation therapy, ... Read more

September 11, 2017September 11, 2017

Long-Term Data Further Confirm SpaceOAR Hydrogel Quality-of-Life Benefits

News

Prostate cancer patients who received the SpaceOAR hydrogel before radiation therapy continue to report benefits five years after treatment, including better urinary and sexual function, a new study reported. ... Read more

September 8, 2017September 8, 2017

Aptevo Regains Rights to Prostate Cancer Therapy APVO414, Whose Results Improve After Delivery Method Tweaked

News

Aptevo Therapeutics has ended its partnership with MorphoSys AG for the development and commercialization of APVO414 as a treatment for metastatic castration resistant prostate cancer, or mCRPC. The termination means the company ... Read more

September 7, 2017

PSA Screening Lowers Mortality, Analysis of Clinical Trials Concludes

News

Prostate cancer screening using prostate-specific antigen (PSA) does reduce mortality in prostate cancer, according to a review that used a new approach to analyze data from large clinical trials. ... Read more

September 6, 2017September 6, 2017

Statin Use Following Prostate Cancer Diagnosis May Reduce Risk of Death, Danish Study Finds

News

Men who began taking statins after being diagnosed with prostate cancer were less like to die than men not on statins, found a Danish study that urged more research ... Read more